<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00637377</url>
  </required_header>
  <id_info>
    <org_study_id>91689</org_study_id>
    <secondary_id>2007-000583-25</secondary_id>
    <nct_id>NCT00637377</nct_id>
  </id_info>
  <brief_title>Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD)</brief_title>
  <acronym>VIEW 2</acronym>
  <official_title>A Randomized, Double Masked, Active Controlled, Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects With Neovascular Age-related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase III, double-masked, randomized, study of the efficacy and safety of
      VEGF Trap-Eye in patients with neovascular age-related macular degeneration. Approximately
      1200 patients will be randomized in Europe, Asia, Japan, Australia and South America.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data of this trial (&quot;VIEW 2&quot;) was pooled with data of a sister trial (&quot;VIEW 1&quot;, NCT00509795),
      and an integrated analyses of the combined data was performed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Maintained Vision at Week 52 - Last Observation Carried Forward (LOCF)</measure>
    <time_frame>At week 52</time_frame>
    <description>Maintenance of vision was defined as a loss of &lt; 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 - LOCF</measure>
    <time_frame>Baseline and at week 52</time_frame>
    <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 - LOCF</measure>
    <time_frame>At week 52</time_frame>
    <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 - LOCF</measure>
    <time_frame>Baseline and at week 52</time_frame>
    <description>The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 - LOCF</measure>
    <time_frame>Baseline and at week 52</time_frame>
    <description>CNV area values measured in square millimeters; lower values represent better outcomes.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1240</enrollment>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5mg Q4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab</intervention_name>
    <description>Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
    <arm_group_label>Ranibizumab 0.5mg Q4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)</intervention_name>
    <description>Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
    <arm_group_label>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Men and women &gt;/=50 years of age.

          -  Active primary or recurrent subfoveal CNV lesions secondary to AMD, including
             juxtafoveal lesions that affect the fovea as evidenced by Fluorescein angiography (FA)
             in the study eye.

          -  ETDRS Best-Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to
             20/320) in the study eye at 4 meters.

          -  Willing, committed, and able to return for ALL clinic visits and complete all
             study-related procedures.

          -  Able to read, (or, if unable to read due to visual impairment, be read to verbatim by
             the person administering the informed consent or a family member) understand and
             willing to sign the informed consent form.

        Exclusion Criteria:

          -  Any prior ocular (in the study eye) or systemic treatment or surgery for neovascular
             AMD, except dietary supplements or vitamins.

          -  Any prior or concomitant therapy with another investigational agent to treat
             neovascular AMD in the study eye.

          -  Any prior treatment with anti-VEGF agents in the study eye.

          -  Total lesion size &gt;12 disc areas (30.5 mm, including blood, scars and
             neovascularization) as assessed by FA in the study eye.

          -  Subretinal hemorrhages that is either 50% or more of the total lesion area, or if the
             blood is under the fovea and is 1 or more disc areas in size in the study eye (if the
             blood is under the fovea, then the fovea must be surrounded by 270 degrees by visible
             CNV).

          -  Scar or fibrosis making up &gt;50% of the total lesion in the study eye.

          -  Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.

          -  Presence of retinal pigment epithelial tears or rips involving the macula in the study
             eye.

          -  History of any vitreous hemorrhage within 4 weeks prior to Visit 1 in the study eye.

          -  Presence of other causes of CNV in the study eye.

          -  Prior vitrectomy in the study eye.

          -  History of retinal detachment or treatment or surgery for retinal detachment in the
             study eye.

          -  Any history of macular hole of stage 2 and above in the study eye.

          -  Any intraocular or periocular surgery within 3 months of Day 1 on the study eye,
             except lid surgery, which may not have taken place within 1 month of Day 1, as long as
             it is unlikely to interfere with the injection.

          -  History or clinical evidence of diabetic retinopathy, diabetic macular edema or any
             retinal vascular disease other than AMD in either eye.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1023AAQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1122AAI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <state>Ciudad Auton. de Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000ANJ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <zip>X5000IIT</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chatswood</city>
        <state>New South Wales</state>
        <zip>2067</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Parramatta</city>
        <zip>2150</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ribeirão Preto</city>
        <state>Sao Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minas Gerais</city>
        <zip>30150-270</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cali</city>
        <state>Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bogota</city>
        <state>Distrito Capital de Bogotá</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <zip>63400</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <zip>77520</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <zip>10034</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 4</city>
        <zip>14000</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <state>Cedex 12</state>
        <zip>75557</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <state>Cedex 1</state>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyon</city>
        <zip>69006</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Freiburg</city>
        <state>Baden-Württemberg</state>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Württemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tübingen</city>
        <state>Baden-Württemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>München</city>
        <state>Bayern</state>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Regensburg</city>
        <state>Bayern</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darmstadt</city>
        <state>Hessen</state>
        <zip>64297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aachen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Essen</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Köln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48145</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <state>Rheinland-Pfalz</state>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Homburg</city>
        <state>Saarland</state>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>06067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lübeck</city>
        <state>Schleswig-Holstein</state>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1106</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <zip>1133</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ahemedabad - 4</city>
        <state>Gujrat</state>
        <zip>380009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wadala, Mumbai</city>
        <state>Maharashtra</state>
        <zip>400031</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600 006</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbatore</city>
        <state>Tamil Nadu</state>
        <zip>641014</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madurai</city>
        <state>Tamil Nadu</state>
        <zip>625 020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pondicherry</city>
        <state>Tamil Nadu</state>
        <zip>600007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangalore</city>
        <zip>560010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyderabad</city>
        <zip>500 034</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kerala</city>
        <zip>683572</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolkata</city>
        <zip>700073</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mumbai</city>
        <zip>400 050</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Delhi</city>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orissa</city>
        <zip>751 024</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tel Hashomer</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torino</city>
        <zip>10122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <zip>37121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urayasu</city>
        <state>Chiba</state>
        <zip>279-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maebashi</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <zip>060-8604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kita</city>
        <state>Kagawa</state>
        <zip>761-0793</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hirakata</city>
        <state>Osaka</state>
        <zip>573-1191</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Otsu</city>
        <state>Shiga</state>
        <zip>520-2192</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>101-8309</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukushima</city>
        <zip>960-1295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagoshima</city>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggido</state>
        <zip>463 707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>110 744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>137 701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>1009</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <zip>1050</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <state>Distrito Federal</state>
        <zip>06800</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metepec</city>
        <state>México</state>
        <zip>52140</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64480</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <zip>31238</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <zip>06030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>México D.F.</city>
        <zip>04030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiden</city>
        <state>ZA</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1100 DD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <zip>3000 CA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-631</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdansk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <zip>40-760</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poznan</city>
        <zip>61-848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszaa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <zip>3000-548</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto</city>
        <zip>4200-319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>159964</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>168751</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <zip>97517</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <zip>81369</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15705</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valladolid</city>
        <zip>47005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Linköping</city>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <zip>11282</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genève</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Camberley</city>
        <state>Surrey</state>
        <zip>GU16 5UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <zip>BT12 6BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <zip>B4 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>NW1 5QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plymouth</city>
        <zip>PL4 6PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/NCT00509795?term=NCT00509795;rank=1</url>
    <description>Click here to view the data of the twin trial conducted by the collaboration partner.</description>
  </link>
  <link>
    <url>http://www.clinicaltrialsregister.eu/</url>
    <description>Click here to find information about studies related to Bayer Healthcare products conducted in Europe</description>
  </link>
  <results_reference>
    <citation>Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012 Dec;119(12):2537-48. doi: 10.1016/j.ophtha.2012.09.006. Epub 2012 Oct 17. Erratum in: Ophthalmology. 2013 Jan;120(1):209-10.</citation>
    <PMID>23084240</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29.</citation>
    <PMID>24084500</PMID>
  </results_reference>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2008</study_first_submitted>
  <study_first_submitted_qc>March 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2008</study_first_posted>
  <results_first_submitted>December 16, 2011</results_first_submitted>
  <results_first_submitted_qc>December 16, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2012</results_first_posted>
  <last_update_submitted>November 28, 2014</last_update_submitted>
  <last_update_submitted_qc>November 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eye diseases</keyword>
  <keyword>Vision Impairment and Blindness</keyword>
  <keyword>Eyes and Vision</keyword>
  <keyword>Seniors</keyword>
  <keyword>Neovascular Age-Related Macular Degeneration (AMD)</keyword>
  <keyword>Retinal Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Endothelial Growth Factors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 186 study centers in 26 countries. Recruitment period: 21 Apr 2008 - 4 Sep 2009.</recruitment_details>
      <pre_assignment_details>2031 participants were screened, 1240 were randomized and 1204 received at least 1 dose of study drug. 1204 participants were included in the Safety-Analysis Set (SAS). 1202 participants with at least 1 post-baseline measurement were included in the Full-Analysis Set (FAS).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab 0.5mg Q4</title>
          <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
          <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
          <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
          <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="313"/>
                <participants group_id="P3" count="311"/>
                <participants group_id="P4" count="313"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="291">safety population</participants>
                <participants group_id="P2" count="309">safety population</participants>
                <participants group_id="P3" count="297">safety population</participants>
                <participants group_id="P4" count="307">safety population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Treated (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="296"/>
                <participants group_id="P4" count="306"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="281"/>
                <participants group_id="P3" count="274"/>
                <participants group_id="P4" count="284"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other (no further information available)</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab 0.5mg Q4</title>
          <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
          <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
          <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
          <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="291"/>
            <count group_id="B2" value="309"/>
            <count group_id="B3" value="296"/>
            <count group_id="B4" value="306"/>
            <count group_id="B5" value="1202"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.0" spread="9.0"/>
                    <measurement group_id="B2" value="74.1" spread="8.5"/>
                    <measurement group_id="B3" value="74.7" spread="8.6"/>
                    <measurement group_id="B4" value="73.8" spread="8.6"/>
                    <measurement group_id="B5" value="73.9" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Information retrieved from all baseline participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="176"/>
                    <measurement group_id="B3" value="147"/>
                    <measurement group_id="B4" value="175"/>
                    <measurement group_id="B5" value="667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="131"/>
                    <measurement group_id="B5" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity</title>
          <description>Information retrieved from all baseline participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="239"/>
                    <measurement group_id="B2" value="259"/>
                    <measurement group_id="B3" value="241"/>
                    <measurement group_id="B4" value="251"/>
                    <measurement group_id="B5" value="990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <description>Information retrieved from all baseline participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="213"/>
                    <measurement group_id="B2" value="226"/>
                    <measurement group_id="B3" value="219"/>
                    <measurement group_id="B4" value="217"/>
                    <measurement group_id="B5" value="875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="69"/>
                    <measurement group_id="B5" value="257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score</title>
          <description>Information retrieved from 1201/1202 baseline participants. The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).</description>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.90" spread="19.09"/>
                    <measurement group_id="B2" value="70.27" spread="19.41"/>
                    <measurement group_id="B3" value="74.04" spread="18.22"/>
                    <measurement group_id="B4" value="71.30" spread="19.06"/>
                    <measurement group_id="B5" value="72.10" spread="18.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Area of Choroidal Neovascularization (CNV)</title>
          <description>Information retrieved from 1200/1202 baseline participants.</description>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.59" spread="5.34"/>
                    <measurement group_id="B2" value="8.25" spread="5.77"/>
                    <measurement group_id="B3" value="7.70" spread="5.26"/>
                    <measurement group_id="B4" value="7.75" spread="5.52"/>
                    <measurement group_id="B5" value="7.83" spread="5.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline lesion type</title>
          <description>Information retrieved from 1197/1202 baseline participants.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Predominantly classic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="80"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="310"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Minimally classic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="106"/>
                    <measurement group_id="B5" value="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Occult</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="123"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="110"/>
                    <measurement group_id="B5" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline total lesion size</title>
          <description>Information retrieved from 1198/1202 baseline participants.</description>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.01" spread="5.74"/>
                    <measurement group_id="B2" value="8.72" spread="6.14"/>
                    <measurement group_id="B3" value="8.17" spread="5.51"/>
                    <measurement group_id="B4" value="8.22" spread="5.87"/>
                    <measurement group_id="B5" value="8.28" spread="5.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Best Corrected Visual Acuity (BCVA), assessed by ETDRS chart</title>
          <description>Information retrieved from all baseline participants. Only participants with a ETDRS (Early Treatment Diabetic Retinopathy Study) Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye at 4 meters were included; a higher score represents better functioning.</description>
          <units>Letters correctly read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.8" spread="13.5"/>
                    <measurement group_id="B2" value="52.8" spread="13.9"/>
                    <measurement group_id="B3" value="51.6" spread="14.2"/>
                    <measurement group_id="B4" value="51.6" spread="13.9"/>
                    <measurement group_id="B5" value="52.4" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Maintained Vision at Week 52 – Last Observation Carried Forward (LOCF)</title>
        <description>Maintenance of vision was defined as a loss of &lt; 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
        <time_frame>At week 52</time_frame>
        <population>Per-Protocol Set (PPS); imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Maintained Vision at Week 52 – Last Observation Carried Forward (LOCF)</title>
          <description>Maintenance of vision was defined as a loss of &lt; 15 letters in the ETDRS (Early Treatment Diabetic Retinopathy Study) letter score (defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
          <population>Per-Protocol Set (PPS); imputation technique: LOCF</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="274"/>
                <count group_id="O3" value="268"/>
                <count group_id="O4" value="270"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.42"/>
                    <measurement group_id="O2" value="95.62"/>
                    <measurement group_id="O3" value="96.27"/>
                    <measurement group_id="O4" value="95.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>null hypothesis: pi ≤ pc-delta where pi is the probability that a participant maintained vision at week 52 under Aflibercept 2mg Q4, pc is the probability that a participant maintained vision at week 52 under Ranibizumab 0.5mg Q4 and delta is the non-inferiority margin. The null hypothesis is tested calculating a two-sided 95 % confidence using normal approximation of the difference of percentages of participants maintaining vision at week 52 (Ranibizumab 0.5mg Q4 minus Aflibercept 2mg Q4).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin is set to 10. The power is 90 % according to the sample size estimation of the study protocol.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.86</ci_lower_limit>
            <ci_upper_limit>2.46</ci_upper_limit>
            <estimate_desc>The difference is calculated as Ranibizumab minus Aflibercept. A negative value favors the Aflibercept 2mg Q4 group. As adjustment of multiple comparisons a conditional sequence of statistical hypotheses is used with alpha = 0.05.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>null hypothesis: pi ≤ pc-delta where pi is the probability that a participant maintained vision at week 52 under Aflibercept 0.5mg Q4, pc is the probability that a participant maintained vision at week 52 under Ranibizumab 0.5mg Q4 and delta is the non-inferiority margin. The null hypothesis is tested calculating a two-sided 95 % confidence using normal approximation of the difference of percentages of participants maintaining vision at week 52 (Ranibizumab 0.5mg Q4 minus Aflibercept 0.5mg Q4).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin is set to 10. The power is 90 % according to the sample size estimation of the study protocol.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.40</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
            <estimate_desc>The difference is calculated as Ranibizumab minus Aflibercept. A negative value favors the Aflibercept 0.5mg Q4 group. As adjustment of multiple comparisons a conditional sequence of statistical hypotheses is used with alpha = 0.05.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>null hypothesis: pi ≤ pc-delta where pi is the probability that a participant maintained vision at week 52 under Aflibercept 2mg Q8, pc is the probability that a participant maintained vision at week 52 under Ranibizumab 0.5mg Q4 and delta is the non-inferiority margin. The null hypothesis is tested calculating a two-sided 95 % confidence using normal approximation of the difference of percentages of participants maintaining vision at week 52 (Ranibizumab 0.5mg Q4 minus Aflibercept 2mg Q8).</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority margin is set to 10. The power is 90 % according to the sample size estimation of the study protocol.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.81</ci_lower_limit>
            <ci_upper_limit>2.55</ci_upper_limit>
            <estimate_desc>The difference is calculated as Ranibizumab minus Aflibercept. A negative value favors the Aflibercept 2mg Q8 group. As adjustment of multiple comparisons a conditional sequence of statistical hypotheses is used with alpha = 0.05.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 – LOCF</title>
        <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.</description>
        <time_frame>Baseline and at week 52</time_frame>
        <population>Full-Analysis Set (FAS); imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 52 – LOCF</title>
          <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.</description>
          <population>Full-Analysis Set (FAS); imputation technique: LOCF</population>
          <units>Letters correctly read</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.4" spread="13.5"/>
                    <measurement group_id="O2" value="7.6" spread="12.6"/>
                    <measurement group_id="O3" value="9.7" spread="14.1"/>
                    <measurement group_id="O4" value="8.9" spread="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline ETDRS letter score as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.076</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-1.9484</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.1009</ci_lower_limit>
            <ci_upper_limit>0.2040</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 2mg Q4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline ETDRS letter score as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9555</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-0.0620</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2398</ci_lower_limit>
            <ci_upper_limit>2.1158</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 0.5mg Q4</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline ETDRS letter score as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4131</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-0.9014</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0615</ci_lower_limit>
            <ci_upper_limit>1.2587</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 2mg Q8 group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 – LOCF</title>
        <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
        <time_frame>At week 52</time_frame>
        <population>Full-Analysis Set; imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Gained at Least 15 Letters of Vision in the ETDRS Letter Score in the Study Eye at Week 52 – LOCF</title>
          <description>Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 25 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning.
Nominator = (Number of participants who maintained vision * 100); Denominator = Number of participants analyzed.</description>
          <population>Full-Analysis Set; imputation technique: LOCF</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="309"/>
                <count group_id="O3" value="296"/>
                <count group_id="O4" value="306"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.02"/>
                    <measurement group_id="O2" value="29.45"/>
                    <measurement group_id="O3" value="34.80"/>
                    <measurement group_id="O4" value="31.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the two proportions are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.229</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.02</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 2mg Q4 group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the two proportions are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.843</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.91</ci_lower_limit>
            <ci_upper_limit>8.46</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 0.5mg Q4 group</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the two proportions are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.490</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.18</ci_lower_limit>
            <ci_upper_limit>4.88</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors the Aflibercept 2mg Q8 group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 – LOCF</title>
        <description>The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).</description>
        <time_frame>Baseline and at week 52</time_frame>
        <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 52 – LOCF</title>
          <description>The possible range of the NEI VFQ-25 total score is between 0 (worst possible) and 100 (best possible).</description>
          <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
                <count group_id="O2" value="304"/>
                <count group_id="O3" value="290"/>
                <count group_id="O4" value="299"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="14.8"/>
                    <measurement group_id="O2" value="4.5" spread="15.0"/>
                    <measurement group_id="O3" value="5.1" spread="13.7"/>
                    <measurement group_id="O4" value="4.9" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline NEI VFQ-25 total score as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0097</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-2.7885</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9012</ci_lower_limit>
            <ci_upper_limit>-0.6757</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 2mg Q4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline NEI VFQ-25 total score as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3917</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-0.9320</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.0658</ci_lower_limit>
            <ci_upper_limit>1.2019</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 0.5mg Q4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline NEI VFQ-25 total score as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0717</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-1.9470</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.0659</ci_lower_limit>
            <ci_upper_limit>0.1718</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A positive value favors Aflibercept 2mg Q8.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 – LOCF</title>
        <description>CNV area values measured in square millimeters; lower values represent better outcomes.</description>
        <time_frame>Baseline and at week 52</time_frame>
        <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
            <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
            <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Choroidal Neovascularization (CNV) Area at Week 52 – LOCF</title>
          <description>CNV area values measured in square millimeters; lower values represent better outcomes.</description>
          <population>Full-Analysis Set with assessment for this outcome measure; imputation technique: LOCF</population>
          <units>mm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="294"/>
                <count group_id="O3" value="287"/>
                <count group_id="O4" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.16" spread="5.90"/>
                    <measurement group_id="O2" value="-5.95" spread="6.12"/>
                    <measurement group_id="O3" value="-4.24" spread="6.13"/>
                    <measurement group_id="O4" value="-5.16" spread="5.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline CNV area as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-1.180</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.979</ci_lower_limit>
            <ci_upper_limit>-0.382</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A negative value favors Aflibercept 2mg Q4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline CNV area as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6784</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>0.170</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.632</ci_lower_limit>
            <ci_upper_limit>0.972</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A negative value favors Aflibercept 0.5mg Q4.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The pairwise comparison is performed as contrast statement in the analysis of covariance model with treatment group as fixed factor (all 4 treatment groups) and the baseline CNV area as covariate. The null hypothesis is that both mean changes are equal.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0727</p_value>
            <p_value_desc>as adjustment of multiple comparisons a conditional sequence of statistical hypotheses (a-priori ordered hypotheses) is used with alpha = 0.05.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Differences in Least Squares means</param_type>
            <param_value>-0.733</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.534</ci_lower_limit>
            <ci_upper_limit>0.068</ci_upper_limit>
            <estimate_desc>The difference is calculated as Aflibercept minus Ranibizumab. A negative value favors Aflibercept 2mg Q8.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab 0.5mg Q4</title>
          <description>Participants received a dose of 0.5 mg Ranibizumab every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q4</title>
          <description>Participants received a dose of 2.0 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 0.5mg Q4</title>
          <description>Participants received a dose of 0.5 mg Aflibercept Injection every 4 weeks for the first year (intravitreal [IVT] injection). Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Aflibercept Injection (EYLEA, VEGF Trap-Eye) 2mg Q8</title>
          <description>Participants received a dose of 2.0 mg Aflibercept Injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year (IVT injection) and were to receive sham injections at interim monthly visits. During the second year, participants received 2.0 mg aflibercept as frequently as every 4 weeks, but no less frequently than every 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Coronary artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cataract cortical</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cataract nuclear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cataract subcapsular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Choroidal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hyphaema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Iridocyclitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Posterior capsule opacification</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal pigment epitheliopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ocular retrobulbar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal pigment epithelial tear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular scar</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Colonic polyp</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Femoral hernia, obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Enterovesical fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bowel movement irregularity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Disease progression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Herpes zoster ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Peridiverticular abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Graft thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Meniscus lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Spinal column injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood osmolarity decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Mean cell haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Mean cell volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Investigation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Benign salivary gland neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bladder cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bladder cancer stage 0, with cancer in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Carcinoid tumour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Colon cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Metastases to ovary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dementia Alzheimer's type</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hypertensive encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Normal pressure hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Petit mal epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vaginal prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Pemphigus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Blepharoplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Strangulated hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Haematoma evacuation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vaginal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="254" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="259" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="251" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="260" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular cyst</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="42" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal cyst</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="70" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="82" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal oedema</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Retinal pigment epitheliopathy</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="31" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Choroidal neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="28" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Age-related macular degeneration</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="307"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="309"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="297"/>
                <counts group_id="E4" subjects_affected="34" subjects_at_risk="307"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Confidentiality agreement with sponsor, contract with the sponsor via the CRO (Clinical research organization), set up based on local legal requirements, changes addressed+confirmed with local responsible persons; PIs interested in presenting the study on meetings, contacted the sponsor and received slides and approval to do so either by the Clinical Lead or the Medical Affairs department</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The conditional sequence of hypothesis testing had to stop after testing the first superiority hypothesis. Therefore, all further statistical tests are exploratory tests.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

